Cas:137206-73-6 5-bromo-7-ethyl-1-benzofuran-2-carbaldehyde manufacturer & supplier

We serve Chemical Name:5-bromo-7-ethyl-1-benzofuran-2-carbaldehyde CAS:137206-73-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

5-bromo-7-ethyl-1-benzofuran-2-carbaldehyde

Chemical Name:5-bromo-7-ethyl-1-benzofuran-2-carbaldehyde
CAS.NO:137206-73-6
Synonyms:5-BROMO-7-ETHYL-2-FORMYL-BENZOFURAN;5-Bromo-7-ethyl-2-benzofurancarboxaldehyde;5-bromo-7-ethyl-benzofuran-2-carbaldehyde
Molecular Formula:C11H9BrO2
Molecular Weight:253.09200
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:343.383ºC at 760 mmHg
Density:1.515g/cm3
Index of Refraction:1.643
PSA:30.21000
Exact Mass:251.97900
LogP:3.57020

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 5-BROMO-7-ETHYL-2-FORMYL-BENZOFURAN chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5-bromo-7-ethyl-benzofuran-2-carbaldehyde physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,5-BROMO-7-ETHYL-2-FORMYL-BENZOFURAN Use and application,5-BROMO-7-ETHYL-2-FORMYL-BENZOFURAN technical grade,usp/ep/jp grade.


Related News: INSPIRE is a global, multi-center, randomized, controlled study to assess the efficacy and safety of IV rigosertib in higher-risk MDS (HR-MDS) patients who had progressed on, failed to respond to, or relapsed after previous treatment with a hypomethylating agent (HMA) within nine cycles over the course of one year after initiation of HMA treatment. 5-bromo-7-ethyl-1-benzofuran-2-carbaldehyde manufacturer The Big Pharma had, however, decided to all but shelve donanemab in the near term as it couldn’t see a regulatory path forward. 5-bromo-7-ethyl-1-benzofuran-2-carbaldehyde supplier INSPIRE is a global, multi-center, randomized, controlled study to assess the efficacy and safety of IV rigosertib in higher-risk MDS (HR-MDS) patients who had progressed on, failed to respond to, or relapsed after previous treatment with a hypomethylating agent (HMA) within nine cycles over the course of one year after initiation of HMA treatment. 5-bromo-7-ethyl-1-benzofuran-2-carbaldehyde vendor With the advancement of supply-side structural reforms, the production of bulk APIs in China will become more concentrated, and the technology will be further improved. 5-bromo-7-ethyl-1-benzofuran-2-carbaldehyde factory Also, states with higher obesity rates also tend to have higher rates of food insecurity, which means lower incomes in general,” she noted. “Bariatric surgery is an expensive proposition, especially if one does not have good insurance coverage for it.